The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
TC BioPharm
Holytown, United Kingdom
A
11-50 Employees
2013
Key takeaway
TC BioPharm is focused on developing advanced allogeneic CAR-T cell therapy products aimed at treating cancer more effectively and affordably. Their mission emphasizes innovation in cell-based therapies to improve patient health and quality of life.
Highlighted product
Core business
Home • TC BioPharm
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.
Leucid Bio
London, United Kingdom
A
11-50 Employees
2014
Key takeaway
Leucid Bio is focused on developing next-generation CAR-T therapies, utilizing their proprietary Lateral CAR platform to enhance treatment outcomes for patients with refractory cancers. Their innovative approach, backed by 20 years of research, aims to improve the efficacy and durability of CAR-T cell therapies, including their T4 Immunotherapy for untreatable head and neck cancer.
Highlighted product
Core business
Home | Leucid bio
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
coding.bio
Oxford, United Kingdom
A
1-10 Employees
2021
Key takeaway
Coding.bio is leveraging an AI-first approach and high-throughput screening to design and discover advanced CARs, aiming to enhance CAR-T cell therapy and provide curative therapeutics to patients. They are actively seeking partnerships to advance CAR-based therapeutics and ensure successful clinical outcomes.
Highlighted product
Core business
coding.bio | ML for CAR discovery
coding.bio is accelerating CAR-T development through Machine Learning and Automation
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Autolus
London, United Kingdom
A
101-250 Employees
2014
Key takeaway
Autolus is dedicated to developing advanced autologous T cell therapies, specifically focusing on Chimeric Antigen Receptor T Cell (CAR-T) therapy, which has the potential to significantly benefit cancer patients. The company's commitment to innovative gene therapies and ongoing clinical trials underscores its role in advancing CAR-T technology.
Highlighted product
Product
Chimeric Antigen Receptor T Cell therapy | Technology | Autolus
Autolus uses Chimeric Antigen Receptors (CARs) to reprogram its T cell product candidates.
Biosceptre International Limited
Cambridge, United Kingdom
A
11-50 Employees
-
Key takeaway
Biosceptre is at the forefront of innovation in multi-targeted CAR-T cell therapy, collaborating with global experts and research institutes to enhance this groundbreaking oncology treatment. CAR-T therapy involves engineering a patient's T cells to express chimeric antigen receptors, enabling them to better target cancer cells.
Highlighted product
Product
CAR T – Biosceptre
CAR T WHAT IS CAR T? CAR T-cell therapy is the engineering of a patient’s T cells, a type of white blood cell. A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen receptors (CAR’s) on the cell surface. The chimeric antigen
Kuur Therapeutics
London, United Kingdom
A
51-100 Employees
2005
Key takeaway
Kuur Therapeutics is at the forefront of developing innovative CAR-T cell therapies, specifically focusing on engineered CAR-NKT cell therapies that leverage the unique biology of natural killer T cells. This approach holds promise for creating effective treatments targeting both hematological and solid tumors.
Highlighted product
Core business
Kuur Therapeutics | Kuur Therapeutics
Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT...
Cytoseek
Bristol, United Kingdom
A
1-10 Employees
2017
Key takeaway
CytoSeek is focused on advancing cell therapies for cancer, particularly through their innovative membrane engineering platform that enhances the effectiveness of treatments against solid tumours. Their approach involves developing therapies that utilize immune cells in combination with their Artificial Membrane-Binding Protein technology, which allows for the targeted delivery of therapeutic proteins.
Highlighted product
Product
Technology — CytoSeek
Our Artificial Membrane-Binding Protein technology allows therapeutic proteins to be coated on the surface of cells without genetic modification. We are leveraging this technology to develop new treatments for cancers.
T-Therapeutics Ltd
Cambridge, United Kingdom
A
11-50 Employees
2022
Key takeaway
T-Therapeutics is pioneering TCR-based therapeutics through its OpTiMus® platform, which generates unique, antigen-specific human TCRs. Their innovative approach harnesses the natural power of T cells to effectively target and destroy tumors, positioning them at the forefront of cancer immunotherapy development.
Highlighted product
Core business
Home - T-Therapeutics
ADAPTIMMUNE LIMITED
Vale of White Horse, United Kingdom
A
- Employees
2007
Key takeaway
Adaptimmune is focused on advancing CAR-T cell therapy through its innovative SPEAR T-cells, which are designed to target challenging solid tumors by utilizing a patient's own cells. The company is on the brink of commercializing the first engineered T-cell therapy for solid tumors, underscoring its commitment to transforming cancer treatment.
Highlighted product
Product
Technology :: Adaptimmune Therapeutics plc (ADAP)
Adaptimmune is revolutionizing cancer therapy by developing TCR T-cell therapies (called SPEAR T-cells). Find out how more about these treatments.
Ori Biotech
London, United Kingdom
A
1-10 Employees
2015
Key takeaway
Ori Biotech is revolutionizing Cell and Gene Therapy (CGT) manufacturing with its innovative Ori manufacturing platform, which enhances throughput, quality, and reduces costs. This advancement is crucial for increasing patient access to personalized, lifesaving treatments like CAR-T therapies, which have already benefited thousands since their approval.
Highlighted product
Core business
Cell and Gene Therapy Manufacturing | Ori Biotech
An innovator in Cell and Gene Therapy with a proprietary, flexible manufacturing platform to enable widespread access to lifesaving treatments
Technologies which have been searched by others and may be interesting for you:
When exploring the CAR-T cell therapy industry in the United Kingdom, several key considerations are crucial. Regulatory frameworks, primarily governed by the Medicines and Healthcare products Regulatory Agency (MHRA), play a significant role in the approval and monitoring of CAR-T therapies. Understanding the Clinical Trials Regulation is vital for navigating the developmental landscape of these therapies. The industry faces challenges such as high production costs and the complexity of treatment protocols, which can limit accessibility for patients. However, there are substantial opportunities for growth, particularly with advancements in genetic engineering and the increasing prevalence of certain cancers, driving demand for innovative treatments. The competitive landscape is evolving, with both established pharmaceutical companies and emerging biotech firms vying for market share. Collaborations with academic institutions and research organizations are common, fostering innovation and development. Environmental concerns are becoming more prominent, particularly regarding the sustainability of manufacturing processes and biological waste management. On a global scale, the UK's position as a leader in biotechnology and research enhances its relevance in the CAR-T market, attracting investments and partnerships. Overall, understanding these dynamics is essential for anyone interested in the CAR-T cell therapy sector in the UK.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | United Kingdom |
| Amount of fitting manufacturers | 685 |
| Amount of suitable service providers | 642 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2005 |
| Youngest suiting company | 2022 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of CAR-T Cell Therapy?
Start-Ups who are working in CAR-T Cell Therapy are coding.bio, T-Therapeutics Ltd
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Biotechnology, Healthcare, Other, IT, Software and Services, Pharmaceuticals
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
